Peg IFNα-2a in polycythemia vera (PV).: Results of a phase 2 study by the French "PV-NORD" group.

被引：0
|
作者：
Kiladjian, Jean-Jacques
Cassinat, Bruno
Turlure, Pascal
Cambier, Nathalie
Bellucci, Sylvia
Roussel, Murielle
Grange, Marie-Jose
Grandchamp, Bernard
Rain, Jean-Didier
Chomienne, Christine
Fenaux, Pierre
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] Hop St Louis, Paris, France
[3] CHU, Limoges, France
[4] CHRU, Lille, France
[5] Hop Lariboisiere, Paris, France
[6] Hop Bichat, F-75877 Paris, France
[7] Hop Bichat, INSERM, U656, F-75877 Paris, France
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2679
引用
下载
收藏
页码：757A / 757A
页数：1
相关论文
共 50 条
  • [31] Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    De Stefano, Valerio
    Masciulli, Arianna
    Carobbio, Alessandra
    Ghirardi, Arianna
    Carioli, Greta
    Rossi, Elena
    Ciceri, Fabio
    Bonifacio, Massimiliano
    Iurlo, Alessandra
    Palandri, Francesca
    Benevolo, Giulia
    Pane, Fabrizio
    Ricco, Alessandra
    Carli, Giuseppe
    Caramella, Marianna
    Rapezzi, Davide
    Musolino, Caterina
    Siragusa, Sergio
    Rumi, Elisa
    Patriarca, Andrea
    Cascavilla, Nicola
    Mora, Barbara
    Cacciola, Emma
    Mannarelli, Carmela
    Loscocco, Giuseppe Gaetano
    Guglielmelli, Paola
    Gesullo, Francesca
    Betti, Silvia
    Lunghi, Francesca
    Scaffidi, Luigi
    Bucelli, Cristina
    Vianelli, Nicola
    Bellini, Marta
    Finazzi, Maria Chiara
    Tognoni, Giovanni
    Rambaldi, Alessandro
    BLOOD, 2022, 140 : 1797 - 1799
  • [32] Safety and Efficacy of Fedratinib, an Oral, Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (PV) Resistant or Intolerant to Hydroxyurea: Results from a Phase II Dose-Ranging and Dose-Expansion Study
    Pardanani, Animesh
    Harrison, Claire
    Vannucchi, Alessandro
    Shortt, Jake
    Kiladjian, Jean-Jacques
    Martinelli, Giovanni
    Rose, Shelonitda
    Zhang, Jun
    Tefferi, Ayalew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S332 - S333
  • [33] Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rhoades, Susanne Kloeker
    Giles, Jennifer L. K.
    Pitou, Celine
    Jones, Emma
    Walgren, Richard A.
    Prchal, Josef T.
    BLOOD, 2011, 118 (21) : 1213 - 1214
  • [34] RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
    Verstovsek, S.
    Kiladjian, J.
    Waltzman, R. J.
    Sandor, V.
    Lukawy, J.
    Garrett, W. M.
    Malek, K.
    Huber, R. M.
    Vannucchi, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a
    Bjorn, Mads Emil
    de Stricker, Karin
    Kjaer, Lasse
    Ellemann, Karsten
    Hasselbalch, Hans Carl
    BLOOD, 2013, 122 (21)
  • [36] Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)
    Gisslinger, Heinz
    Klade, Christoph
    Georgiev, Pencho
    Krochmalczyk, Dorota
    Gercheva-Kyuchukova, Liana
    Egyed, Miklos
    Dulicek, Petr
    Illes, Arpad
    Pylypenko, Halyna
    Sivcheva, Liliya
    Mayer, Jiri
    Yablokova, Vera
    Krejcy, Kurt
    Empson, Victoria
    Hasselbalch, Hans
    Kralovics, Robert
    Kiladjian, Jean-Jacques
    BLOOD, 2023, 142
  • [37] THE HEMOSTATIC PROFILE OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA (PV) PATIENTS IS INFLUENCED BY THE JAK2V617F ALLELE BURDEN
    Marchetti, M.
    Castoldi, E.
    Russo, L.
    Vignoli, A.
    Rosing, J.
    Ten Cate, H.
    Falanga, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 178 - 178
  • [38] Early results of peg-IFN α-2a treatment in chronic hemodialysis patients with chronic c hepatitis
    Strain, M. H.
    Patrascu, M.
    Strain, R. D.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S146 - S147
  • [39] RUXOLITINIB (RUX) REDUCES JAK2V617F ALLELE BURDEN (AB) IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) ENROLLED IN THE RESPONSE STUDY
    Vannucchi, A. M.
    Verstovsek, S.
    Guglielmelli, P.
    Griesshammer, M.
    Burn, T. C.
    Naim, A.
    Paranagama, D.
    Marker, M.
    Tiecke, E.
    Gadbaw, B.
    Kiladjian, J. J.
    HAEMATOLOGICA, 2016, 101 : 163 - 164
  • [40] PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
    Abdulraheem Yacoub
    Ghaith Abu-Zeinah
    Albert Qin
    Tsewang Tashi
    Waleed Da’na
    Weichung Joe Shih
    Oleh Zagrijtschuk
    Chan-Yen Tsai
    Robert Geller
    Norio Komatsu
    Ruben Mesa
    Harinder Gill
    Annals of Hematology, 2025, 104 (1) : 335 - 345
12345